High cardiovascular event rates occur within the first weeks of starting hemodialysisKai‐Uwe Eckardt, Jürgen Floege, Peter Stenvinkel et al.|Kidney International|2015Cited by 113
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injuryPeter Pickkers, Anne Louise Kjølbye, Derek C. Angus et al.|BMJ Open|2023Cited by 17